亚宝药业：子公司GLX002用于治疗肺动脉高压（PAH）（WHO 第1 组）的临床试验获批

Core Viewpoint - The company announced that its wholly-owned subsidiary, Beijing Yabao Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of GLX002, aimed at treating pulmonary arterial hypertension (PAH) [1] Group 1 - GLX002 is intended to improve pulmonary vascular resistance (PVR) in pediatric patients aged 1 year and older with idiopathic or congenital PAH [1] - The treatment is also aimed at adult patients with WHO functional class II-IV PAH to enhance exercise capacity and reduce clinical deterioration [1]